TY - JOUR
T1 - Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia
AU - Lauriello, John
AU - McEvoy, Joseph P.
AU - Rodriguez, Stephen
AU - Bossie, Cynthia A.
AU - Lasser, Robert A.
N1 - Funding Information:
This study was supported by Janssen Medical Affairs.
PY - 2005/1/1
Y1 - 2005/1/1
N2 - Maintenance treatment regimens for patients with schizophrenia are often suboptimal. Partial adherence and outright noncompliance are associated with symptom recurrence and increased likelihood of rehospitalization. Long-acting conventional neuroleptics have limited efficacy and are associated with treatment-limiting adverse events, while oral atypical antipsychotics have not improved adherence substantially. A long-acting formulation of risperidone, an atypical antipsychotic with proven efficacy, has been developed. Introduction of long-acting injectable treatment may be appropriate during inpatient hospitalization, when consequences of relapse are most evident. To support this intervention, a subanalysis of patients who were inpatients at study initiation was conducted from a 12-week, double-blind, placebo-controlled long-acting risperidone study (N=214). Long-acting risperidone was associated with a significant reduction in total Positive and Negative Syndrome Scale (PANSS) score (mean change±standard error [S.E.] at endpoint: long-acting risperidone, -9.27±1.44, n=133; placebo, 0.72±2.59, n=41; P<0.001), and a significantly higher rate of treatment response, defined as ≥20% reduction in total PANSS score (50% vs. 27%, P<0.05). Significantly more long-acting risperidone patients had endpoint Clinical Global Impressions (CGI) assessments of not ill, very mild or mild (32% vs. 5%; P<0.01). Long-acting risperidone was well tolerated. Long-acting risperidone initiated during inpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia.
AB - Maintenance treatment regimens for patients with schizophrenia are often suboptimal. Partial adherence and outright noncompliance are associated with symptom recurrence and increased likelihood of rehospitalization. Long-acting conventional neuroleptics have limited efficacy and are associated with treatment-limiting adverse events, while oral atypical antipsychotics have not improved adherence substantially. A long-acting formulation of risperidone, an atypical antipsychotic with proven efficacy, has been developed. Introduction of long-acting injectable treatment may be appropriate during inpatient hospitalization, when consequences of relapse are most evident. To support this intervention, a subanalysis of patients who were inpatients at study initiation was conducted from a 12-week, double-blind, placebo-controlled long-acting risperidone study (N=214). Long-acting risperidone was associated with a significant reduction in total Positive and Negative Syndrome Scale (PANSS) score (mean change±standard error [S.E.] at endpoint: long-acting risperidone, -9.27±1.44, n=133; placebo, 0.72±2.59, n=41; P<0.001), and a significantly higher rate of treatment response, defined as ≥20% reduction in total PANSS score (50% vs. 27%, P<0.05). Significantly more long-acting risperidone patients had endpoint Clinical Global Impressions (CGI) assessments of not ill, very mild or mild (32% vs. 5%; P<0.01). Long-acting risperidone was well tolerated. Long-acting risperidone initiated during inpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia.
KW - Adherence
KW - Depot
KW - Long-acting antipsychotic
KW - Risperidone
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=9244246782&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9244246782&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2004.05.006
DO - 10.1016/j.schres.2004.05.006
M3 - Article
C2 - 15560969
AN - SCOPUS:9244246782
SN - 0920-9964
VL - 72
SP - 249
EP - 258
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 2-3
ER -